New Research Says: The Biggest Gains of AI Won't Go to AI Stocks. These 2 ETFs Could Be Better Buys.

Vanguard’s June research argues the biggest AI-driven gains may accrue to U.S. value stocks and developed-market ex-U.S. equities rather than current AI hyperscalers. It highlights the Vanguard Small-Cap Value ETF (VBR), up 27.1% over the past year, and notes a low 0.05% expense ratio; and the Vanguard International Dividend Appreciation ETF (VIGI), yielding 2.12% (trailing 12-month) with a 0.07% expense ratio. Overall, the piece is a strategy tilt toward non-hyperscaler exposure to potential AI productivity benefits, but it does not introduce new single-stock catalysts.

Analysis

This is less a direct AI earnings story than a factor-rotation setup: if investors start paying for AI-enabled productivity at the adopter level, the first beneficiaries are cheap operating-leverage names where small efficiency gains fall straight to pre-tax margins. That points to banks and mature cash generators inside VIGI, especially RY, TD, and MUFG, plus defensives like NVS/NSRGY where SG&A leverage can support dividend growth without needing heroic revenue assumptions.

The second-order risk is that this is mostly a flows trade until quarterly numbers prove it. In the next 1-3 months, any real price follow-through likely comes from ETF allocation rather than fundamental revision, so the move can reverse quickly if U.S. mega-cap growth keeps compounding or if global PMIs soften. Over 6-18 months, the thesis only works if management teams actually translate AI pilots into lower expense ratios, lower headcount growth, or better underwriting/claims productivity.

Contrarian take: the market may be underestimating how much of the surplus from AI accrues to the infrastructure layer, not to broad value or ex-U.S. adopters. If cloud, chip, and software vendors continue to capture the economics while customers pay recurring vendor rents, value stocks just get a one-time productivity bump, not a durable re-rating. For VIGI, currency and global growth are the gating variables; for small-cap value, balance-sheet sensitivity and refinancing conditions can easily swamp any AI benefit.

Key Decisions for Investors

• No chase in the first 1-2 sessions; use any dip to build a small tactical long VIGI position only if breadth rotates out of U.S. growth. Target 3-6 months; thesis breaks if QQQ re-accelerates and VIGI lags by >5% on a relative basis.
• Relative-value pair: long VIGI / short QQQ or IWF for a 3-6 month factor rotation trade. Risk/reward improves if earnings season starts showing expense-ratio improvement at RY, TD, or MUFG; cut if growth leadership reasserts itself.
• Watchlist long: RY and TD for an AI-efficiency story with clean capital return profiles. Enter only if next earnings prints show operating leverage or expense guidance improvement; otherwise the thesis is narrative-only.
• Avoid treating NVS/NSRGY as AI winners in the near term; they are better viewed as low-beta compounders that can absorb AI spend without stressing the balance sheet. Best use is defensive ballast, not an alpha catalyst.
• Set a falsifier alert: if developed ex-U.S. financials fail to show visible cost leverage by the next 2 earnings cycles, or if the USD strengthens and global growth rolls over, abandon the AI-adopter thesis and rotate back to U.S. mega-cap growth.